A

Amgen

Makes biotech medicines for serious illnesses

Field Reimbursement Senior Manager

Full-TimePosted on 10/20/2026
$176.9k - $239.3k/yr+ Discretionary annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's, PhD, Associate's
Houston, TX, USA+4 moreMore locations: Los Angeles, CA, USA | Phoenix, AZ, USA | Denver, CO, USA | Portland, OR, USA
In Person
Customer Experience & Support
H1B Sponsorship Available

About the job

Requirements
  • A doctorate degree and 2 years of experience in the public or private third-party access arena or pharmaceutical industry in sales, managed care, or clinical support; or a master's degree and 4 years of such experience; or a bachelor's degree and 6 years; or an associate's degree and 10 years; or a high school diploma/GED and 12 years.
  • A valid driver's license with a clean driving record.
  • Five years of experience as a manager or first-line leader, or demonstrated people leadership experience coaching, developing, motivating, and managing performance of others.
  • Three years of experience in field reimbursement, managed care, market access, clinical support, or a related access role in the public or private third-party access arena or pharmaceutical/biotechnology industry.
  • Expertise in Specialty Pharmacy and Buy & Bill reimbursement, including prior authorization, appeals/denials, coding, billing, claims, benefit design, and patient support programs, with the ability to lead a team supporting a dual-benefit product model.
  • Understanding of commercial payer, Medicare, and Medicaid access and reimbursement dynamics, and the ability to interpret payer policy and translate changes into field action.
  • Ability to lead and coach account management, business planning, and customer engagement within a field-based reimbursement organization.
  • Strategic planning, analytical reasoning, and fact-based decision-making skills, including interpreting quantitative and qualitative data, field KPIs, payer policy, account insights, and performance trends.
  • Ability to build a strong team culture, establish clear expectations, create accountability, and manage individual and team performance.
  • Cross-functional leadership and collaboration skills to influence outcomes across a complex matrix organization.
  • Commitment to ethical, legal, and compliance standards and experience leading teams within established field reimbursement rules of engagement.
  • Presentation, facilitation, coaching, and communication skills for interacting with field teams, customers, cross-functional partners, and senior leadership.
  • Organizational and project management skills, including managing multiple priorities, leading change, and ensuring timely follow-through.
  • Experience using CRM and performance-management tools to monitor field execution, identify trends, and support coaching and business decisions.
  • Experience in healthcare, including physician offices or clinics, specialty pharmacy, HUB services, insurance verification, claim adjudication, or pharmaceutical/biotechnology manufacturers.
  • Ability to travel up to 60–80% by automobile or plane, based on geography and business needs.
  • Ability to meet established field-time and coaching expectations and engage in person across the assigned region.
Responsibilities
  • Lead, coach, develop, and retain a high-performing team of Field Reimbursement Managers through clear expectations, regular coaching, field observations, meaningful feedback, performance management, and development planning.
  • Build and sustain a team culture grounded in accountability, collaboration, inclusion, trust, and positive momentum; recognize strong performance, address challenges, and reinforce company values and leadership behaviors.
  • Set performance expectations and hold the team accountable for field KPIs, service-level expectations, customer engagement measures, and business objectives; use performance data to identify trends, address gaps, and strengthen execution.
  • Meet senior-manager field-time and coaching expectations and ensure regional field presence to observe customer engagement, coach FRMs, assess market dynamics, and stay connected to customer access experiences.
  • Ensure the team delivers an excellent access experience through reimbursement expertise, responsive customer engagement, issue resolution, appropriate follow-through, and compliant execution.
  • Develop and execute regional strategies that translate national access priorities into territory and account plans, using payer, account, market, competitive, channel, and performance insights to identify access barriers and opportunities.
  • Coach FRMs to use account-management principles, analytical reasoning, and fact-based decision-making to prioritize accounts and resources, develop account-specific access strategies, and adapt execution based on performance and market insights.
  • Maintain expertise in Specialty Pharmacy and Buy & Bill reimbursement and ensure the team can navigate the dual-benefit product model.
  • Monitor national, regional, and local payer dynamics, reimbursement policy, competitive landscape, channel trends, reimbursement economics, and stakeholder practices; translate relevant insights into regional strategy and team execution.
  • Lead compliant cross-functional collaboration with Sales, Key Account Management, Market Access, Medical, HUB, Operations, Training, and other partners to align access priorities, resolve barriers, and improve customer experience within established rules of engagement.
  • Lead regional business reviews and performance discussions integrating field KPIs, account insights, payer trends, access barriers, and opportunities; set actions and ensure follow-through.
  • Identify, escalate, and help resolve systemic access, reimbursement, process, or operational issues; communicate insights and recommended actions to leadership and cross-functional partners.
  • Ensure team compliance with business rules, policies, procedures, privacy requirements, and field reimbursement rules through coaching, field observations, virtual engagement, and performance management.
  • Partner with Training and Capability Development to identify skill gaps, support onboarding, reinforce reimbursement and account-management capabilities, and advance team development.
  • Drive operational excellence through regional planning, resource prioritization, expense management, CRM adoption, timely documentation, escalation management, and consistent process execution.
  • Hire and onboard talent, build succession and development plans, and empower team members to grow, take ownership, and deliver results.
  • Build trusted relationships and align stakeholders around access priorities and customer needs through influence across a complex matrix organization.
Desired Qualifications
  • A bachelor's degree in business, healthcare, or a related field.
  • Previous experience leading a field reimbursement team supporting specialty pharmaceutical or biologic products, and/or launching new products or indications.
  • Advanced experience with dual-benefit products and the operational differences between Specialty Pharmacy and physician-administered Buy & Bill channels.
  • Knowledge of Managed Care, Government and Federal payer sectors, Integrated Delivery Networks/Integrated Health Systems, and regional payer dynamics.
  • Advanced knowledge of medical insurance terminology, CMS policies and processes, reimbursement regulations, coding, coverage, and payment methodologies.
  • Experience developing talent, assessing readiness, building succession plans, and coaching leaders or future leaders.
  • Experience leading business reviews and using performance measures, market insights, and customer feedback to improve field execution and access experience.
  • Experience partnering with training, operations, HUB, technology, and other enabling functions to improve field capabilities and processes.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.